Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Atrial natriuretic peptide and regulation of vascular function in hypertension and heart failure: implications for novel therapeutic strategies.

Rubattu S, Calvieri C, Pagliaro B, Volpe M.

J Hypertens. 2013 Jun;31(6):1061-72. doi: 10.1097/HJH.0b013e32835ed5eb. Review.

PMID:
23524910
2.

Error occurred: cannot get document summary

PMID:
27754186

3.

Potentiation of natriuretic peptides by neutral endopeptidase inhibitors.

Seymour AA, Abboa-Offei BE, Smith PL, Mathers PD, Asaad MM, Rogers WL.

Clin Exp Pharmacol Physiol. 1995 Jan;22(1):63-9. Review.

PMID:
7768036
4.

[Natriuretic peptide system].

Itoh H, Nakao K.

Nihon Rinsho. 1997 Aug;55(8):1923-36. Review. Japanese.

PMID:
9284403
5.

[Atrial natriuretic peptide. II. Pathophysiology and possible clinical significance. Review].

Vollmar AM.

Tierarztl Prax. 1990 Aug;18(4):319-22. Review. German.

PMID:
2145657
6.

Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance.

Abassi Z, Karram T, Ellaham S, Winaver J, Hoffman A.

Pharmacol Ther. 2004 Jun;102(3):223-41. Review.

PMID:
15246247
7.

Vasopeptidase inhibition: a new concept in blood pressure management.

Burnett JC Jr.

J Hypertens Suppl. 1999 Feb;17(1):S37-43. Review.

PMID:
10340842
8.

Natriuretic peptides and their therapeutic potential.

Cho Y, Somer BG, Amatya A.

Heart Dis. 1999 Nov-Dec;1(5):305-28. Review.

PMID:
11720638
9.

Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives.

Kjaer A, Hesse B.

Clin Physiol. 2001 Nov;21(6):661-72. Review.

PMID:
11722473
10.
11.

Effects of exogenous and endogenous natriuretic peptides on forearm vascular function in chronic heart failure.

Schmitt M, Gunaruwan P, Payne N, Taylor J, Lee L, Broadley AJ, Nightingale AK, Cockcroft JR, Struthers AD, Tyberg JV, Frenneaux MP.

Arterioscler Thromb Vasc Biol. 2004 May;24(5):911-7. Epub 2004 Mar 4.

12.

Role of nitric oxide as a key mediator on cardiovascular actions of atrial natriuretic peptide in spontaneously hypertensive rats.

Costa MA, Elesgaray R, Caniffi C, Fellet A, Mac Laughlin M, Arranz C.

Am J Physiol Heart Circ Physiol. 2010 Mar;298(3):H778-86. doi: 10.1152/ajpheart.00488.2009. Epub 2009 Sep 25.

13.
14.

Clearance receptors and endopeptidase: equal role in natriuretic peptide metabolism in heart failure.

Rademaker MT, Charles CJ, Kosoglou T, Protter AA, Espiner EA, Nicholls MG, Richards AM.

Am J Physiol. 1997 Nov;273(5 Pt 2):H2372-9.

15.

Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?

Corti R, Burnett JC Jr, Rouleau JL, Ruschitzka F, Lüscher TF.

Circulation. 2001 Oct 9;104(15):1856-62. Review.

16.
17.

Practical implications of current natriuretic peptide research.

Sagnella GA.

J Renin Angiotensin Aldosterone Syst. 2000 Dec;1(4):304-15. Review.

PMID:
11967816
18.

Mechanisms of mechanical load-induced atrial natriuretic peptide secretion: role of endothelin, nitric oxide, and angiotensin II.

Ruskoaho H, Leskinen H, Magga J, Taskinen P, Mäntymaa P, Vuolteenaho O, Leppäluoto J.

J Mol Med (Berl). 1997 Nov-Dec;75(11-12):876-85. Review.

PMID:
9428620
19.

The natriuretic peptides in heart failure: diagnostic and therapeutic potentials.

Chen HH, Burnett JC Jr.

Proc Assoc Am Physicians. 1999 Sep-Oct;111(5):406-16. Review.

PMID:
10519161
20.

[Conditions of secretion and peripheral effects of atrial natriuretic peptide in heart failure].

Riegger AJ.

Z Kardiol. 1988;77 Suppl 5:77-86. Review. German.

PMID:
2975895

Supplemental Content

Support Center